BofA analyst Jason Gerberry raised the firm’s price target on Johnson & Johnson to $221 from $220 and keeps a Neutral rating on the shares. The firm “modestly” increased its 2026 sales and EPS estimates following J&J’s “solid” Q4 report, but thinks J&J’s premium multiple “encapsulates the current consensus growth outlook” and notes that it is more cautious on the new product cycle.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $250 from $232 at Citi
- Johnson & Johnson price target raised to $240 from $230 at Wells Fargo
- Johnson & Johnson: Solid Fundamentals but Fully Valued with Litigation Overhang Supporting Hold Rating
- Johnson & Johnson Projects Strong Growth Beyond STELARA
- Midday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s